Anti-PD-1 + thymosin + SOX

The combination "Anti-PD-1 + thymosin + SOX" appears to be an investigational treatment regimen being studied for gastric or esophagogastric junctional cancer. This combination includes an anti-PD-1 immune checkpoint inhibitor, thymosin (likely thymosin alpha-1), and SOX (likely referring to the chemotherapy regimen combining S-1 and oxaliplatin). Anti-PD-1 inhibitors block the interaction between PD-1 receptors on T-cells and PD-L1 on cancer cells, thereby enhancing the immune system's ability to detect and destroy cancer cells. Thymosin alpha-1 is an immunomodulatory peptide that can enhance T-cell function and promote immune system activation, potentially working synergistically with immune checkpoint inhibitors. The SOX component likely refers to a chemotherapy combination of S-1 (an oral fluoropyrimidine) and oxaliplatin, which is commonly used in gastric cancer treatment. According to the search results, this combination is being studied specifically in the neoadjuvant setting for clinical stage III gastric or esophagogastric junctional cancers.